# Syndax Pharmaceuticals Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Syndax Pharmaceuticals Inc). ## Overview Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases. Its business centers on oncology and immunology products, including Revuforj and Niktimvo, supported by a pipeline of product candidates and collaboration arrangements. ## Products & services • Revuforj (revumenib) for hematologic cancers • Niktimvo (axatilimab-csfr) for cGVHD • Clinical development of oncology and immunology candidates • Product commercialization, distribution and market access • Collaboration and licensing arrangements - **Commercial products** (80%) — Approved and marketed therapies sold in the United States, including Revuforj and Niktimvo. - **Collaboration revenue** (20%) — Revenue recognized from co-commercialization and partner arrangements, including Incyte. - **Clinical-stage pipeline** (0%) — Investigational oncology and immunology programs being advanced through trials and regulatory work. - Revuforj (revumenib) for hematologic cancers - Niktimvo (axatilimab-csfr) for cGVHD - Clinical development of oncology and immunology candidates - Product commercialization, distribution and market access - Collaboration and licensing arrangements ## Customers Syndax sells primarily into the U.S. specialty pharmaceutical channel, where specialty distributors and specialty pharmacies resell products to healthcare providers and patients. Its commercial focus is on hematologists, oncologists, and transplant physicians, especially in academic and community treatment settings. Collaboration revenue also reflects partner-led commercialization and profit-sharing structures. - **Specialty distributors** (primary) — Buy Revuforj and distribute it onward to pharmacies and providers in the specialty drug channel. - **Specialty pharmacies** (primary) — Dispense oncology medicines and manage access, reimbursement, and patient fulfillment. - **Hematology and oncology physicians** (primary) — Prescribe Revuforj for eligible cancer patients based on clinical need and label. - **Transplant physicians** (primary) — Prescribe Niktimvo for chronic graft-versus-host disease after prior therapies fail. - **Commercial partners** (secondary) — Partners such as Incyte support global commercialization and revenue-sharing arrangements. - Specialty distributors that purchase Revuforj for resale - Specialty pharmacies serving oncology and transplant patients - Hematologists and oncologists prescribing in cancer centers - Transplant physicians treating cGVHD and related conditions - Commercial partners such as Incyte in co-commercialized products ## Geography Syndax is headquartered in the United States and its current commercial activity is concentrated there. The company also references the European Union and other major markets as future pricing and reimbursement environments for its products, reflecting potential international expansion through partners. Manufacturing is outsourced, so geography matters mainly through commercial access, regulatory approval, and third-party supply chains rather than owned production sites. - United States is the core commercial market for Revuforj and Niktimvo - Commercial field force is built around U.S. hematology and oncology centers - European Union is a referenced future market for pricing and reimbursement - Outside the U.S., commercialization is expected to rely on partners - Manufacturing is outsourced to third-party contract manufacturers ## Strategy Syndax’s strategy is to build a commercial franchise around Revuforj and Niktimvo while continuing to advance its clinical pipeline. The company relies on targeted specialty sales, partner-led commercialization outside the U.S., and outsourced manufacturing to keep its operating model focused on drug development and launch execution. It also seeks milestone, royalty, and collaboration economics from partnerships to broaden its revenue base. - **Commercialize Revuforj and Niktimvo** (short-term) — Product sales and collaboration economics depend on successful launch execution and access. - **Build partner-supported global reach** (medium-term) — The company lacks broad direct international infrastructure and uses partners to extend reach. - **Advance pipeline and regulatory approvals** (medium-term) — Future growth depends on additional approved products and label expansion. - Expand commercialization of Revuforj in the U.S. - Co-commercialize Niktimvo with Incyte in the U.S. - Use partners for ex-U.S. development and sales - Advance clinical candidates in oncology and immunology - Rely on contract manufacturing instead of owned plants ## Risks Syndax depends heavily on successful commercialization of a small number of products, so demand, reimbursement, and launch execution are central risks. It also faces typical biopharma risks such as clinical trial failure, regulatory setbacks, competition, manufacturing dependence on third parties, and pricing pressure from payors and government programs. - **Commercialization may underperform expectations** [high] — The company relies on Revuforj and Niktimvo adoption in specialty oncology channels. - **Pricing and reimbursement pressure** [high] — Government and third-party payors can limit net realized pricing and access. - **Clinical and regulatory failure** [high] — Pipeline value depends on successful trials and approvals, which are uncertain. - **Competition in oncology and immunology** [medium] — Competing therapies can reduce market share and slow adoption. - **Third-party manufacturing dependence** [medium] — The company does not own manufacturing facilities and relies on contract manufacturers. - Revenue concentration in a small number of launched products - Reimbursement and pricing pressure from U.S. and EU payors - Clinical trial and regulatory approval uncertainty - Competition from other oncology and biotech companies - Third-party manufacturing and supply chain dependence ## Accounting Revenue recognition is highly judgmental because product sales are recorded net of discounts, chargebacks, rebates, returns, and other deductions, and collaboration revenue depends on ASC 808 profit-sharing mechanics. The company also has meaningful estimates around clinical trial accruals, royalty interest expense from the Royalty Pharma transaction, and foreign currency remeasurement on trade payables. Because launches are recent, quarterly revenue and expense patterns can be uneven as commercialization scales. - **Net product revenue deductions** — Affects reported sales and gross-to-net volatility - **Collaboration accounting under ASC 808** — Affects collaboration revenue and operating results - **Clinical trial accruals** — Can shift quarterly R&D expense timing - **Royalty interest financing liability** — Affects financing costs and future cash flows - **Foreign currency remeasurement** — Can create non-operating volatility - Net product revenue depends on gross-to-net deductions - Collaboration revenue reflects ASC 808 profit-sharing - Clinical trial costs are accrued based on progress estimates - Royalty interest expense relates to Royalty Pharma financing - Foreign currency remeasurement affects other expense --- *Last updated: 2026-04-29T05:01:04.068573+00:00*